Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Once-weekly vs Twice-weekly Carfilzomib + Len/Dex in RRMM
NCT03859427Phase 3Completed
- Sponsor
- Amgen
- Start
- May 2019
- Primary completion
- Mar 2023
- Modality
- Irreversible Covalent Inhibitors, Reversible Covalent Inhibitors
- Countries
- 17
01
Overview
Phase 3, randomised, open-label trial of carfilzomib in multiple myeloma (MM) (2 arms), sponsored by Amgen. Primary endpoint: Overall Response Rate at 12 months. Started May 2019; status: completed.
02
Drugs
carfilzomib
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT03859427.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03859427.